Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC

[1]  R. Yantiss,et al.  The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms , 2020, Annals of Surgical Oncology.

[2]  R. Yantiss,et al.  The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms , 2020, Cancer.

[3]  A. Blaes,et al.  Impact of adjuvant chemotherapy on outcomes in appendiceal cancer , 2020, Cancer medicine.

[4]  N. Aydin,et al.  Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  K. Geisinger,et al.  Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy , 2014, Journal of surgical oncology.

[6]  R. Wolff,et al.  Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Sugarbaker,et al.  Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin , 2010, Journal of surgical oncology.

[8]  H. Lippert,et al.  Primary appendiceal carcinoma--epidemiology, surgery and survival: results of a German multi-center study. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.